• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于癌症干细胞特征开发用于评估肺腺癌预后的5基因特征。

Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells.

作者信息

Wan Renping, Liao Hongliang, Liu Jingting, Zhou Lin, Yin Yingqiu, Mu Tianhao, Wei Jie

机构信息

Department of Thoracic Surgery, Yuebei People's Hospital, 133 Huimin South Road, Wujiang District, Shaoguan City, Guangdong Province, China 440200.

Department of Respiratory Medicine, Yuebei People's Hospital, 133 Huimin South Road, Wujiang District, Shaoguan City Guangdong Province, China 440200.

出版信息

Biomed Res Int. 2022 Apr 16;2022:4404406. doi: 10.1155/2022/4404406. eCollection 2022.

DOI:10.1155/2022/4404406
PMID:35480140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9036162/
Abstract

Cancer stem cells (CSCs) can induce recurrence and chemotherapy resistance of lung adenocarcinoma (LUAD). Reliable markers identified based on CSC characteristic of LUAD may improve patients' chemotherapy response and prognosis. OCLR was used to calculate mRNA expression-based stemness index (mRNAsi) of LUAD patients' data in TCGA. Association analysis of mRNAsi was performed with clinical features, somatic mutation, and tumor immunity. A prognostic prediction model was established with LASSO Cox regression. Kaplan-Meier Plotter (KM-plotter) and time-dependent ROC were applied to assess signature performance. For LUAD, univariate and multivariate Cox analysis was performed to identify independent prognostic factors. LUAD tissues showed a noticeably higher mRNAsi in than nontumor tissues, and it showed significant differences in T, N, M, AJCC stages, and smoking history. The most frequently mutated gene was TP53, with a higher mRNAsi relating to more frequent mutation of TP53. The mRNAsi was significantly negatively correlated with immune score, stromal score, and ESTIMATE score in LUAD. The blue module was associated with mRNAsi. The 5-gene signature was confirmed as an independent indicator of LUAD prognosis that could promote personalized treatment of LUAD and accurately predict overall survival (OS) of LUAD patients.

摘要

癌症干细胞(CSCs)可导致肺腺癌(LUAD)复发和化疗耐药。基于LUAD的CSC特征鉴定出的可靠标志物可能会改善患者的化疗反应和预后。利用OCLR计算了TCGA中LUAD患者数据基于mRNA表达的干性指数(mRNAsi)。对mRNAsi与临床特征、体细胞突变和肿瘤免疫进行了关联分析。采用LASSO Cox回归建立了预后预测模型。应用Kaplan-Meier Plotter(KM-plotter)和时间依赖的ROC评估特征性能。对于LUAD,进行单因素和多因素Cox分析以确定独立的预后因素。LUAD组织的mRNAsi明显高于非肿瘤组织,且在T、N、M、AJCC分期和吸烟史方面存在显著差异。最常发生突变的基因是TP53,mRNAsi越高,TP53的突变频率越高。在LUAD中,mRNAsi与免疫评分、基质评分和ESTIMATE评分显著负相关。蓝色模块与mRNAsi相关。5基因特征被确认为LUAD预后的独立指标,可促进LUAD的个性化治疗并准确预测LUAD患者的总生存期(OS)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/d8adbab53fab/BMRI2022-4404406.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/e97c3ac5300f/BMRI2022-4404406.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/a0f52323348c/BMRI2022-4404406.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/9f67d1ceea8f/BMRI2022-4404406.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/5c1ba7c10050/BMRI2022-4404406.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/fe311b545bb9/BMRI2022-4404406.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/37ee16aa59e2/BMRI2022-4404406.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/6b2b44153308/BMRI2022-4404406.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/d2fd0439c51f/BMRI2022-4404406.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/315a9f0ba7ad/BMRI2022-4404406.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/4f275a0096ff/BMRI2022-4404406.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/d8adbab53fab/BMRI2022-4404406.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/e97c3ac5300f/BMRI2022-4404406.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/a0f52323348c/BMRI2022-4404406.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/9f67d1ceea8f/BMRI2022-4404406.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/5c1ba7c10050/BMRI2022-4404406.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/fe311b545bb9/BMRI2022-4404406.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/37ee16aa59e2/BMRI2022-4404406.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/6b2b44153308/BMRI2022-4404406.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/d2fd0439c51f/BMRI2022-4404406.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/315a9f0ba7ad/BMRI2022-4404406.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/4f275a0096ff/BMRI2022-4404406.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d91a/9036162/d8adbab53fab/BMRI2022-4404406.011.jpg

相似文献

1
Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells.基于癌症干细胞特征开发用于评估肺腺癌预后的5基因特征。
Biomed Res Int. 2022 Apr 16;2022:4404406. doi: 10.1155/2022/4404406. eCollection 2022.
2
Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.基于癌症干性的肺腺癌和肺鳞癌预后免疫相关基因特征。
Front Endocrinol (Lausanne). 2021 Oct 21;12:755805. doi: 10.3389/fendo.2021.755805. eCollection 2021.
3
Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.通过全面分析和验证揭示与癌症免疫和预后相关的免疫和干性相关基因及其在肺腺癌中的列线图。
Front Immunol. 2022 Jun 27;13:829057. doi: 10.3389/fimmu.2022.829057. eCollection 2022.
4
Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.通过干性指数和加权相关网络分析鉴定肺腺癌中的癌症干细胞相关标志物。
J Cancer Res Clin Oncol. 2020 Jun;146(6):1463-1472. doi: 10.1007/s00432-020-03194-x. Epub 2020 Mar 28.
5
mRNAsi Index: Machine Learning in Mining Lung Adenocarcinoma Stem Cell Biomarkers.mRNAsi 指数:在挖掘肺腺癌干细胞生物标志物方面的机器学习应用。
Genes (Basel). 2020 Feb 27;11(3):257. doi: 10.3390/genes11030257.
6
The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma.肿瘤干细胞指标 mRNAsi 可作为肺腺癌的分子分型工具。
Biochem Genet. 2023 Dec;61(6):2401-2424. doi: 10.1007/s10528-023-10388-8. Epub 2023 Apr 26.
7
Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.综合分析包含脂质代谢和免疫相关基因的新型标志物,用于评估肺腺癌的预后和免疫图谱。
Front Immunol. 2022 Aug 25;13:950001. doi: 10.3389/fimmu.2022.950001. eCollection 2022.
8
Construction and validation of a prognostic model for stemness-related genes in lung adenocarcinoma.肺腺癌干性相关基因预后模型的构建与验证
Transl Cancer Res. 2024 Mar 31;13(3):1351-1366. doi: 10.21037/tcr-23-1847. Epub 2024 Mar 11.
9
Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.早期肺腺癌中与 TP53 相关的免疫景观和有前途的免疫预后模型。
Cancer Med. 2021 Feb;10(3):806-823. doi: 10.1002/cam4.3655. Epub 2020 Dec 12.
10
scRNA-seq revealed high stemness epithelial malignant cell clusters and prognostic models of lung adenocarcinoma.scRNA-seq 揭示了肺腺癌中具有高干性的上皮恶性细胞簇和预后模型。
Sci Rep. 2024 Feb 14;14(1):3709. doi: 10.1038/s41598-024-54135-4.

引用本文的文献

1
Analysis and identification of mRNAsi‑related expression signatures via RNA sequencing in lung cancer.通过RNA测序分析和鉴定肺癌中与mRNAsi相关的表达特征
Oncol Lett. 2024 Sep 13;28(5):549. doi: 10.3892/ol.2024.14682. eCollection 2024 Nov.
2
Retracted: Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells.撤回:基于癌症干细胞特征开发用于评估肺腺癌预后的5基因特征。
Biomed Res Int. 2024 Mar 20;2024:9867431. doi: 10.1155/2024/9867431. eCollection 2024.
3
Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.

本文引用的文献

1
A Lipid Metabolism-Based Seven-Gene Signature Correlates with the Clinical Outcome of Lung Adenocarcinoma.基于脂质代谢的七基因特征与肺腺癌临床结局相关。
J Oncol. 2022 Feb 11;2022:9913206. doi: 10.1155/2022/9913206. eCollection 2022.
2
TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression.基于 TKI 耐药的 LUAD 预后免疫相关基因特征,其中 FSCN1 有助于肿瘤进展。
Cancer Lett. 2022 Apr 28;532:215583. doi: 10.1016/j.canlet.2022.215583. Epub 2022 Feb 9.
3
Identification of seven-gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi-omics data analysis.
全面评估碱基切除修复(BER)相关长链非编码 RNA 作为肺腺癌的预后和功能生物标志物:对个性化治疗和免疫调节的影响。
J Cancer Res Clin Oncol. 2023 Dec;149(19):17199-17213. doi: 10.1007/s00432-023-05435-1. Epub 2023 Oct 3.
4
The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma.肿瘤干细胞指标 mRNAsi 可作为肺腺癌的分子分型工具。
Biochem Genet. 2023 Dec;61(6):2401-2424. doi: 10.1007/s10528-023-10388-8. Epub 2023 Apr 26.
利用整合多组学数据分析鉴定预测肺腺癌患者生存的七个基因标志物。
J Clin Lab Anal. 2022 Feb;36(2):e24190. doi: 10.1002/jcla.24190. Epub 2021 Dec 23.
4
Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.TTN突变对肺腺癌患者免疫微环境及免疫治疗疗效的影响
Front Oncol. 2021 Aug 26;11:725292. doi: 10.3389/fonc.2021.725292. eCollection 2021.
5
A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.一个新的与铁死亡相关的基因签名,用于预测肺腺癌患者的预后。
Aging (Albany NY). 2021 Jun 11;13(12):16144-16164. doi: 10.18632/aging.203140.
6
A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD).一种七基因预后特征可预测肺腺癌(LUAD)患者的总生存期。
Cancer Cell Int. 2021 Jun 6;21(1):294. doi: 10.1186/s12935-021-01975-z.
7
Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes.基于代谢相关基因的肺腺癌预后标志物的建立与验证
Cancer Cell Int. 2021 Apr 15;21(1):219. doi: 10.1186/s12935-021-01915-x.
8
Upregulation of GNPNAT1 Predicts Poor Prognosis and Correlates With Immune Infiltration in Lung Adenocarcinoma.GNPNAT1的上调预示肺腺癌预后不良并与免疫浸润相关。
Front Mol Biosci. 2021 Mar 25;8:605754. doi: 10.3389/fmolb.2021.605754. eCollection 2021.
9
Plakophilin-2 Promotes Lung Adenocarcinoma Development via Enhancing Focal Adhesion and Epithelial-Mesenchymal Transition.桥粒芯蛋白2通过增强黏着斑和上皮-间质转化促进肺腺癌发展。
Cancer Manag Res. 2021 Jan 22;13:559-570. doi: 10.2147/CMAR.S281663. eCollection 2021.
10
Immune Resistance in Lung Adenocarcinoma.肺腺癌中的免疫抵抗
Cancers (Basel). 2021 Jan 21;13(3):384. doi: 10.3390/cancers13030384.